Company
The Company DNA
CANNORDIC A/S is a pioneering MedTech company specializing in innovative substance-based medical devices containing bioactive CBD. Our dedication to enhancing lives by integrating innovation, science, technology, and natural cannabis compounds positions it as a pioneer in the medical technology industry. The company ensures robust research, development, manufacturing, compliance, data insights, and commercialization processes. R&D: Develop safe and effective treatments for pain and autoimmune diseases while exploring new ideas with potential life-improving capabilities. All development, clinical trials, and technical files are linked to production and compliance. Regulatory Compliance: Ensures all products meet stringent regulatory standards, facilitating market entry and establishment globally. Manufacturing and Commercialization: Focuses on global business contracts and producing finished products.
History
Purpose
World-changing products for a better every day.
Our purpose is to drive change to treatments, built upon our knowledge of the endocannabinoid system, the benefits of cannabis, and our experience in the pharmaceutical industry.
We envision a world where patient care has proven efficacy but fewer side effects for pain relief, transforming 2 or 4-legged patients’ symptoms for a better every day, globally.
Vision
Improve people’s quality of life by merging innovation, science, and nature within healthcare.
Mission
At CANNORDIC, our mission is to bring change and relief to patients’ lives worldwide with the therapeutic values of cannabinoids. We have a scientific approach based on biochemistry and decades of experience within the global medical industry. We use modern technology to research different compounds found in the cannabis plant to prevent and fight autoimmune diseases and stress-related disorders effectively and safely. From science-based development to high-quality world-changing products and partnerships, we commit to improving people’s lives with products that make a difference.
Value Propositioning
A trusted MedTech Partner Science is in our nature. Balance and Recover. Relief and Confidence. Quality and Safety. Responsibility & Commitment.
Structure
CS MEDICA
CS MEDICA GROUP DNA and Positioning: The Group defines the company’s core identity and market positioning, supporting various entities and global operations.
IPRs, Patents, and Trademarks: Centralized under CS MEDICA, these support all activities across different entities, safeguarding innovation.
Operational and Marketing Functions: Centralized to provide efficient support, including operational processes, marketing & branding, patient and market insights, and oversight of patents and intellectual property rights (IPRs), ensuring a competitive edge.
GALAXAPHARMA A/S
Restructuring Impact: Sales and distribution for CANNASEN® products will be integrated into CANNORDIC A/S, allowing GALAXA PHARMA to focus on distributing pharmaceutical and prescription-based products, enhancing overall distribution efficiency.
CANNORDIC A/S
Regulatory Compliance: Ensures all products meet stringent regulatory standards, facilitating market entry and establishment globally.
Manufacturing and Commercialization: Focuses on global business contracts and producing finished products.
CANNORDIC INDIA
Strategic Advantage: Leveraging India’s manufacturing capabilities to produce high-quality products at lower costs, increasing global competitiveness and ensuring a solid commercialization impact in a large market.
RongShi Medica
Future Expansion: Envisioned as a manufacturing and distribution hub for the Asian markets, currently on hold due to funding delays.
Team
Despite obstacles, our commitment to delivering excellence and innovation remains persistent. It’s in these challenging moments that our resilience intensifies, and our ability to adjust becomes an essential asset.
Strengthening our DNA of R&D with knowledge of market penetration and registrations, patient needs, and how-to insights ensures we can increasingly predict and stay agile, navigating with science and data-driven decisions for long-term, sustainable growth.
Board
Board composition
Once a year, the Board of Directors will conduct a self-evaluation to ensure that the Board promotes the Company’s purpose and serves the culture and values of the Company.
To ensure constructive, proactive value-creating discussions, the Board of Directors aims at ensuring the right composition and balance of competencies in the Board. Consequently, it is the mission of the Board of Directors to find competencies within scaling and internationalization MedTech/Pharma businesses while also looking to organize itself with Board members that hold solid experience and a strong track record from large, listed companies. To have an equal distribution of men and women on the Board of Directors, hence the least represented gender on the Board should comprise no less than 40% in accordance with the Danish Business Authority’s guidelines on equal gender distribution on the Board of Directors. Currently the Board is under self-evaluation to map the need for optimal adaptive resources and to ensure a match to the 40% gender distribution rule.
The Board of Directors has adapted the following policies:
- Rules of Procedure for the Board of Directors
- Instructions for the CEO
- Information and Communication Policy
- Insider Policy